Meet The Professors: Pancreatic Cancer Edition, 2016 - Video 6Rationale for the use of nal-IRI
1:29 minutes.
TRANSCRIPTION:
DR BEKAII-SAAB: The whole concept of a nanoliposomal formulation is essentially, you take a lot more, so in this case 80,000 irinotecan molecules. And you pack them into a liposome. And essentially you have this extended circulation, so that MM-398, or nanoliposomal irinotecan, continues to go through. And then think about squirting the chemotherapy into the tumor every time you reach the area. And so that was the whole concept. And the first study was actually a Phase II study that looked at — and it was published with the first author, Andrew Ko from UCSF — that essentially suggested that there is a promise for this agent in refractory metastatic pancreas cancer patients who fail gemcitabine. This is an ongoing study that essentially looked at the leakage rate and intratumoral concentration of the agents. And essentially it was very predictable, with only 3% leakage rate into the circulation, which does explain why the toxicity profile of this regimen is no different than irinotecan, whereby there was higher levels of SN-38 intratumorally, which would be expected, again, from the nanoliposomal formulation. |